Equities research analysts forecast that Viking Therapeutics Inc (NASDAQ:VKTX) will report earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 18.2%. The company is expected to report its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.40). For the next year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).

VKTX has been the topic of a number of recent analyst reports. CIBC initiated coverage on Viking Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating and a $12.00 price target on the stock. ValuEngine raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Stifel Nicolaus initiated coverage on Viking Therapeutics in a research report on Tuesday, June 25th. They set a “buy” rating and a $14.00 price target on the stock. BidaskClub downgraded Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Finally, Oppenheimer initiated coverage on Viking Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. Viking Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.53.

NASDAQ VKTX traded down $0.20 during trading on Friday, reaching $6.83. 11,380 shares of the company’s stock were exchanged, compared to its average volume of 2,445,925. The firm’s 50 day simple moving average is $7.90. The firm has a market capitalization of $507.64 million, a PE ratio of -17.12 and a beta of 2.29. Viking Therapeutics has a fifty-two week low of $6.68 and a fifty-two week high of $24.00.

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Viking Therapeutics by 30.6% in the fourth quarter. Geode Capital Management LLC now owns 594,510 shares of the biotechnology company’s stock valued at $4,548,000 after purchasing an additional 139,420 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Viking Therapeutics in the first quarter valued at approximately $880,000. Hikari Power Ltd boosted its stake in shares of Viking Therapeutics by 25.0% in the first quarter. Hikari Power Ltd now owns 50,000 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 10,000 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Viking Therapeutics in the first quarter valued at approximately $126,000. Finally, Bailard Inc. boosted its stake in shares of Viking Therapeutics by 109.5% in the first quarter. Bailard Inc. now owns 312,200 shares of the biotechnology company’s stock valued at $3,103,000 after buying an additional 163,200 shares during the period. 62.91% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.